Nga Thi Nguyen

Ms. Nga Thi Nguyen

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 May 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
Chirag VasavdaChirag Vasavda
Chirag Vasavda
GWGuihong Wan
Guihong Wan
MSMindy D. Szeto
Mindy D. Szeto
MMMelika Marani
Melika Marani
NSNishadh Sutaria
Nishadh Sutaria
SKShawn G. Kwatra
Shawn G. Kwatra

1 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Jeovanis Gil ValdesJeovanis Gil Valdes
Jeovanis Gil Valdes
MRMelinda Rezeli
Melinda Rezeli
ELElmar Gregor Lutz
Elmar Gregor Lutz
YKYonghyo Kim
Yonghyo Kim
YSYutaka Sugihara
Yutaka Sugihara
György Marko-VargaGyörgy Marko-Varga
György Marko-Varga
Melanoma in advanced stages is one of the most aggressive tumors and the deadliest of skin cancers. To date, the histopathological staging focuses on tumor thickness, and clinical staging is a major estimate of the clinical behavior of primary melanoma. Here we report on an observational study with in-depth molecular profiling at the protein level including post-translational modifications (PTMs) on eleven primary tumors from melanoma patients. Global proteomics, phosphoproteomics, and acetylomics were performed on each sample. We observed an up-regulation of key mitochondrial functions, including the mitochondrial translation machinery and the down-regulation of structural proteins involved in cell adhesion, the cytoskeleton organization, and epidermis development, which dictates the progression of the disease. Additionally, the PTM level pathways related to RNA processing and transport, as well as chromatin organization, were dysregulated in relation to the progression of melanoma. Most of the pathways dysregulated in this cohort were enriched in genes differentially expressed at the transcript level when similar groups are compared or metastasis to primary melanomas. At the genome level, we found significant differences in the mutation profiles between metastatic and primary melanomas. Our findings also highlighted sex-related differences in the molecular profiles. Remarkably, primary melanomas in women showed higher levels of antigen processing and presentation, and activation of the immune system response. Our results provide novel insights, relevant for developing personalized precision treatments for melanoma patients.

12 November 2020 in Current Geriatrics Reports
Verified
Journal Article
Closed access
PDF file
NNNga Thi Nguyen
Nga Thi Nguyen
SCSarah Corley
Sarah Corley

23 June 2025 in medRxiv
Verified
Preprint
Open access
PDF file
GWGuihong Wan
Guihong Wan
NNNga Thi Nguyen
Nga Thi Nguyen
CLCharles Lu
Charles Lu
SKSara Khattab
Sara Khattab
BYBoshen Yan
Boshen Yan
YSYevgeniy Semenov
Yevgeniy Semenov
Background Systemic immunosuppression (sISP), particularly with glucocorticoids, is commonly used among patients receiving immune checkpoint inhibitor (ICI) therapy. Although recent studies have demonstrated that sISP is associated with poor outcomes in ICI recipients, there is limited information on how the timing, dose, and duration of sISP affect overall survival (OS). This multi-cohort retrospective study aims to address these gaps. Methods This study included 13,086 ICI recipients from Massachusetts General Hospital, Brigham and Women’s Hospital, and Dana-Farber Cancer Institute (MGBD) between May 31, 2015, and October 11, 2021. For independent validation, 26,172 ICI recipients were identified from the TriNetX database between April 30, 2010, and October 11, 2021, using 2:1 propensity score matching. Multivariable survival analyses were conducted with Accelerated Failure Time (AFT) models, reporting Time Ratios (TRs) and 95% Confidence Intervals (CIs), where TR<1 indicates shorter OS. Findings In the MGBD cohort, sISP within one year of ICI initiation was associated with worse OS compared to patients without sISP via landmark analysis. This association was accentuated among patients receiving sISP closer to ICI initiation, with those receiving sISP within one month of ICI initiation having the worst outcomes (TR: 0.49; 95% CI: 0.44-0.54; p<0.0001). Increased dose and duration of sISP were associated with a greater survival time loss, such that doses beyond 60 mg/day had a 40% survival time loss and durations longer than 7 days were associated with a 35% survival time loss. These findings were independently validated in the TriNetX cohort. Interpretation Three key factors are associated with significantly worse OS: sISP near ICI initiation, higher sISP dose, and longer sISP duration, regardless of indication. These findings provide clinicians with valuable information to guide sISP management among ICI recipients. Funding NIH, USA Evidence before this study We reviewed PubMed and existing literature for studies on systemic immunosuppression (sISP), particularly glucocorticoids, and outcomes among immune checkpoint inhibitor (ICI) recipients. Previous research, including clinical trial studies, indicated that sISP, especially at higher doses or for managing immune-related adverse events (irAEs), was associated with poorer survival. However, studies were limited by small sample sizes, focused on single cancer types, or did not comprehensively assess the nuanced impacts of sISP timing relative to ICI initiation, dose, and duration across diverse cancer types and ICI indications. Thus, a clear understanding of these specific parameters in large, real-world cohorts was lacking. Added value of this study This multi-cohort study analyzed approximately 40,000 ICI recipients, leveraging data from a large academic medical center system (MGBD) and validating findings in a national, population-level database (TriNetX) with access to granular patient-level data. We comprehensively investigated how the timing, dose, and duration of systemic glucocorticoid immunosuppression influence overall survival across a pan-cancer population. Our large scale and detailed approach provide robust, generalizable insights into these critical factors, addressing limitations of prior, smaller, or more narrowly focused investigations. Implications of all the available evidence Our findings offer clinicians critical, actionable insights for managing systemic glucocorticoid immunosuppression in patients receiving ICI therapy. Knowing that sISP administered near ICI initiation, at higher doses, or for longer durations is associated with significantly worse overall survival can guide clinical decision-making. This allows for more informed risk-benefit discussions, strategies to minimize steroid exposure when feasible (e.g., lowest effective dose, shortest duration), and consideration of steroid-sparing alternatives, ultimately aiming to optimize survival outcomes for cancer patients on ICI therapy.